Founded in 2019 and based in San Raffaele Hospital (Milan, Italy), Biorek s.r.l is developing an innovative test for the screening, diagnosis and prognosis of the Renal Cell Carcinoma (RCC) by basing on genetic and molecular biomarkers derived from liquid biopsies, such as whole blood and urines. The company lead assets allow them to identify biomarkers able to: detect the presence of a renal mass, distinguish patients having a malignant mass from those having a benign one and finally determine the level of aggressivity of the renal carcinoma. Such biomarkers will be used in screening tests and will allow to improve the accuracy and specificity of diagnosis and prognosis in the field of RCC. Biorek approach derives from the ability of its team members of putting together medical and scientific expertise along with the entrepreneurial one. By doing so, Biorek aims to speed up the entire process which bring the scientific results from bench directly to the bedside.
Location: Italy, Lombardy, Milan
Employees: 1-10
Investors 1
| Date | Name | Website |
| - | Health Tec... | hthvc.com |